weight loss glp 1 agonists Study finds GLP-1 receptor target fat over muscle for GLP-1 receptor agonists | How

The 2024 Standards of Care in Diabetes does emphasize use of certain GLP-1 medications over others for certain goals

[3] A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)

Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol

2009, pp

"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas"

From a mechanistic standpoint, this dual action explains why the same class can be used for both diabetes and weight management